253 related articles for article (PubMed ID: 16570917)
1. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.
de Gouville AC; Boullay V; Krysa G; Pilot J; Brusq JM; Loriolle F; Gauthier JM; Papworth SA; Laroze A; Gellibert F; Huet S
Br J Pharmacol; 2005 May; 145(2):166-77. PubMed ID: 15723089
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
Higashiyama H; Yoshimoto D; Kaise T; Matsubara S; Fujiwara M; Kikkawa H; Asano S; Kinoshita M
Exp Mol Pathol; 2007 Aug; 83(1):39-46. PubMed ID: 17274978
[TBL] [Abstract][Full Text] [Related]
5. Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
Li HY; Wang Y; Yan L; Campbell RM; Anderson BD; Wagner JR; Yingling JM
Bioorg Med Chem Lett; 2004 Jul; 14(13):3585-8. PubMed ID: 15177480
[TBL] [Abstract][Full Text] [Related]
6. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases.
de Gouville AC; Huet S
Drug News Perspect; 2006 Mar; 19(2):85-90. PubMed ID: 16628263
[TBL] [Abstract][Full Text] [Related]
8. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
Fu K; Corbley MJ; Sun L; Friedman JE; Shan F; Papadatos JL; Costa D; Lutterodt F; Sweigard H; Bowes S; Choi M; Boriack-Sjodin PA; Arduini RM; Sun D; Newman MN; Zhang X; Mead JN; Chuaqui CE; Cheung HK; Zhang X; Cornebise M; Carter MB; Josiah S; Singh J; Lee WC; Gill A; Ling LE
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):665-71. PubMed ID: 18202322
[TBL] [Abstract][Full Text] [Related]
9. Remote delivery and expression of soluble type II TGF-beta receptor in muscle prevents hepatic fibrosis in rats.
Nakamuta M; Morizono S; Tsuruta S; Kohjima M; Kotoh K; Enjoji M
Int J Mol Med; 2005 Jul; 16(1):59-64. PubMed ID: 15942678
[TBL] [Abstract][Full Text] [Related]
10. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.
Bonniaud P; Margetts PJ; Kolb M; Schroeder JA; Kapoun AM; Damm D; Murphy A; Chakravarty S; Dugar S; Higgins L; Protter AA; Gauldie J
Am J Respir Crit Care Med; 2005 Apr; 171(8):889-98. PubMed ID: 15563636
[TBL] [Abstract][Full Text] [Related]
11. The expression of CSRP2 encoding the LIM domain protein CRP2 is mediated by TGF-beta in smooth muscle and hepatic stellate cells.
Herrmann J; Borkham-Kamphorst E; Haas U; Van de Leur E; Fraga MF; Esteller M; Gressner AM; Weiskirchen R
Biochem Biophys Res Commun; 2006 Jul; 345(4):1526-35. PubMed ID: 16735029
[TBL] [Abstract][Full Text] [Related]
12. A sensitive short-term evaluation of antifibrotic effects using newly established type I collagen reporter transgenic rats.
Terashima H; Kato M; Yasumo H; Tsuchida H; Mizuno M; Sada T
Am J Physiol Renal Physiol; 2010 Oct; 299(4):F792-801. PubMed ID: 20660018
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Beight DW; Britt KS; Anderson BD; Campbell RM; Goodson T; Herron DK; Li HY; McMillen WT; Mort N; Parsons S; Smith EC; Wagner JR; Yan L; Zhang F; Yingling JM
Bioorg Med Chem Lett; 2004 Jul; 14(13):3581-4. PubMed ID: 15177479
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats.
Nakamura T; Sakata R; Ueno T; Sata M; Ueno H
Hepatology; 2000 Aug; 32(2):247-55. PubMed ID: 10915731
[TBL] [Abstract][Full Text] [Related]
15. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ALK5 signaling induces physeal dysplasia in rats.
Frazier K; Thomas R; Scicchitano M; Mirabile R; Boyce R; Zimmerman D; Grygielko E; Nold J; DeGouville AC; Huet S; Laping N; Gellibert F
Toxicol Pathol; 2007 Feb; 35(2):284-95. PubMed ID: 17366323
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy.
Yata Y; Gotwals P; Koteliansky V; Rockey DC
Hepatology; 2002 May; 35(5):1022-30. PubMed ID: 11981752
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
[TBL] [Abstract][Full Text] [Related]
19. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
Li X; Wang L; Long L; Xiao J; Hu Y; Li S
Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
